Determining whether the effect of liraglutide on non‐alcoholic fatty liver disease depends on reductions in the body mass index-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Determining whether the effect of liraglutide on non‐alcoholic fatty liver disease depends on reductions in the body mass index

Published:2020-06-30 Issue:5 Volume:4 Page:995-1001
ISSN:2397-9070
Container-title:JGH Open
language:en
Short-container-title:JGH Open

Author:

Shiomi Megumi¹²^ORCID,Tanaka Yoichi¹,Takada Tesshu³,Otori Katsuya¹²

Affiliation:

1. Department of Clinical Pharmacy, School of Pharmacy Kitasato University Minato‐ku Japan

2. Department of Pharmacy Kitasato University Medical Center Saitama Japan

3. Department of Endocrinology, Diabetes, and Metabolism, School of Medicine Kitasato University Sagamihara Japan

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jgh3.12384

Reference36 articles.

1. Glucagon-like peptide-1 receptor agonists for type 2 diabetes: A rational drug development

2. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults

3. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

4. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients

5. Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive framework for managing metabolic dysfunction-associated steatotic liver disease: analyzing novel risk factors and advances in nanotechnology-based treatments and diagnosis;RSC Medicinal Chemistry;2024

2. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review;European Journal of Clinical Pharmacology;2023-11-08

3. Effect of 5:2 Fasting Diet on Liver Fat Content in Patients with Type 2 Diabetic with Nonalcoholic Fatty Liver Disease;Metabolic Syndrome and Related Disorders;2022-10-01

4. Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease?;Frontiers in Endocrinology;2022-09-02

5. Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs;Antioxidants;2022-05-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3